EPICS

Conference Coverage: EHA 2023 – Focus on AML and MDS

Saturday, June 10, 2023; 18.30 – 21.30 CEST
Live Meeting

Chair: Elias Jabbour, MD

US Faculty
Naval Daver, MD (University of Texas MD Anderson Cancer Center)
Guillermo Garcia-Manero, MD (University of Texas MD Anderson Cancer Center)
Alexander Perl, MD (Abramson Cancer Center, University of Pennsylvania)
Rami Komrokji, MD (Moffitt Cancer Center)
Jessica K. Altman, MD (Robert H. Lurie Comprehensive Cancer Center of Northwestern University)

AGENDA

Time (CEST)	Topic	Presenter
18.30 – 18.35 (5 min)	**Welcome and Introductions**	Elias Jabbour, MD
18.35 – 18.45 (10 min)	**New Developments in First-Line Treatment of Myelodysplastic Syndromes (MDS)** **<u>Low-risk MDS</u>** • KER-050 Treatment Improved Markers of Erythropoietic Activity and Hematopoiesis Over Six Months Which Resulted in Hematological Responses Across a Broad, Lower-Risk MDS Population. Aristoteles Giagounidis, S166 • Luspatercept Versus Epoetin Alfa for Treatment of Anemia in ESA-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions: Data From the Phase 3 COMMANDS Study. Matteo Giovanni Della Porta, S102 • Luspatercept Restores Effective Erythropoiesis and Provides Superior and Sustained Clinical Benefit vs Epoetin Alfa: Biomarker Analysis From the Phase 3 COMMANDS Study. Uwe Platzbecker, P693 **<u>High-risk MDS</u>** • Phase 1/2 Study of Oral Decitabine/Cedazuridine in Combination With Venetoclax in Treatment-Naïve Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia. Alex Bataller, S172	Guillermo Garcia-Manero, MD

18.45 – 19.05 (20 min)	**Discussion** • In your opinion, what are the most impactful data in frontline MDS presented at EHA 2023? – How will you incorporate these new data into your current treatment approach for MDS? • Are there any investigational agents of particular interest, and why? • What remains an unmet clinical need in first-line treatment of MDS?	All
19.05 – 19.15 (10 min)	**New Developments in Treatment of Relapsed/Refractory (R/R) MDS** **<u>MDS with mutations</u>** • Higher *MDMX* Expression Was Associated With Hypomethylating Agent Resistance and Worse Survival in Myelodysplastic Syndrome Patients, Inferring It a Potential Therapeutic Target. Yu-Hung Wang, S171 **<u>R/R MDS</u>** • Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents in IMERGE Phase 3. Uwe Platzbecker, S165 • Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents in IMERGE Phase 3. Valeria Santini, S164 **<u>Other</u>** • Myelodysplastic Neoplasms (MDS) Classification From WHO 2017 to WHO 2022 and ICC 2022: An Expanded Analysis of 7017 Patients on Behalf of the International Consortium for MDS (ICMDS). Rami S. Komrokji, S170	Rami Komrokji, MD
19.15 – 19.35 (20 min)	**Discussion** • In your opinion, what are the most impactful data in R/R MDS presented at EHA 2023? – How will you incorporate these new data into your current treatment approach for MDS? • What is your assessment of novel and emerging agents in the treatment of R/R MDS? • What will be practice changing, and what will open new avenues of scientific investigation? • What remains an unmet clinical need in R/R MDS?	All
19.35 – 19.40 (5 min)	**Key Takeaways for MDS**	Rami Komrokji, MD, and Guillermo Garcia-Manero, MD

19.40 – 19.50 (10 min)	**Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed** **<u>AML with *FLT3*-wt</u>** • FLAG-IDA Combined With Gemtuzumab Ozogamicin (GO) Reduced MRD Levels and Improved Overall Survival in *NPM1*mut AML Independent of *FLT3* and MRD Status, Results From the AML19 Trial. Nigel Russell, S134 • Preliminary Results of QUIWI: A Double Blinded, Randomized Clinical Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients With Newly Diagnosed FLT3-ITD Wild-Type AML. Pau Montesinos, S130 **<u>AML with *FLT3*-mut</u>** • Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission Plus FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia With FLT3-ITD: Results From QuANTUM-First. Richard Schlenk, S137 • Gemtuzumab-Based Induction Chemotherapy Combined With Midostaurin for FLT3 Mutated AML. Updated Toxicity and Interim Survival Analysis From the NCRI AML19V2 “Midotarg” Pilot Trial. Nigel Russell, P484 • Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Acute Myeloid Leukemia With *FLT3* Internal Tandem Duplication Treated With Intensive Chemotherapy Plus Midostaurin. Frank Rücker, S135	Naval Daver, MD
19.50 – 20.15 (25 min)	**Discussion** • In your opinion, what are the most impactful data in newly diagnosed AML presented at EHA 2023? • How do you view the current and emerging data in newly diagnosed AML patients with *FLT3*-mutated or *NPM1*-mutated AML? • Will any of the presented data change your practice? How? • Can you comment on the sequencing of TKIs in *FLT3*-mutated AML patients, and which of these patients do you consider candidates for the different TKI regimens?	All
20.15 – 20.20 (5 min)	**Break**	
20.20 – 20.30 (10 min)	**Advances in AML: Newly Diagnosed Elderly and/or Unfit** • Phase II Study on Venetoclax Plus Decitabine for Elderly (≥60 <75 years) Patients With Newly Diagnosed High-Intermediate Risk AML Eligible for Allo-SCT: Midterm Update of Ven-Dec GITMO Study. Domenico Russo, P502	Alexander Perl, MD

	• Updated Results of VEN-A-QUI Study: A Phase 1-2 Trial to Assess the Safety and Efficacy of Triplets for Newly Diagnosed Unfit AML Patients: Azacitidine or Low-Dose Cytarabine With Venetoclax and Quizartinib. Juan Miguel Bergua Burgues, S132 • A Randomised Assessment of the Sequential Addition of the Kinase Inhibitor Quizartinib to Intensive Chemotherapy in Older Acute Myeloid Leukaemia (AML) Patients: Results From the NCRI AML18 Trial. Steven Knapper, S131	
20.30 – 20.50 (20 min)	**Discussion** • What are your thoughts on the data presented regarding unfit and/or older adults with newly diagnosed AML? • Will any of the presented data change your practice? How? • What are unmet needs in AML treatment?	All
20.50 – 20.55 (5 min)	**Advances in AML: R/R AML** • Olutasidenib in Post-venetoclax Patients With Mutant IDH1 AML. Jorge Cortes, P555 • Venetoclax (Ven) Combined With FLAG-IDA Is an Effective Regimen for Patients (pts) With Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Madelyn Burkart, P545 • Updated Data for Ziftomenib in Patients With NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia. Amir Fathi, P504	Jessica K. Altman, MD
20.55 – 21.20 (25 min)	**Discussion** • What is your preferred treatment approach, and how do you view the presented data in the real-life setting for R/R AML? • What is your assessment of new and emerging targets in R/R AML? • Will any of the presented data change your practice? How?	All
21.20 – 21.25 (5 min)	**Key Takeaways**	Naval Daver, MD; Alexander Perl, MD; Jessica K. Altman, MD
21.25 – 21.30 (5 min)	**Summary and Closing Remarks**	Elias Jabbour, MD

Total time: 3 hours